vs
PROCORE TECHNOLOGIES, INC.（PCOR）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
PROCORE TECHNOLOGIES, INC.的季度营收约是Bio-Techne的1.2倍（$359.3M vs $311.4M），Bio-Techne净利率更高（16.4% vs -2.5%，领先18.9%），PROCORE TECHNOLOGIES, INC.同比增速更快（15.7% vs -1.5%），过去两年PROCORE TECHNOLOGIES, INC.的营收复合增速更高（12.4% vs 1.3%）
Procore Technologies是2002年成立的美国建筑管理软件即服务（SaaS）企业，总部位于加利福尼亚州卡平特里亚。公司打造的全球平台可连接建筑行业从业者，支持搭建简化工作流，统一展现建筑项目信息，覆盖任务追踪、项目流程管理、日程排期等核心功能。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
PCOR vs TECH — 直观对比
营收规模更大
PCOR
是对方的1.2倍
$311.4M
营收增速更快
PCOR
高出17.2%
-1.5%
净利率更高
TECH
高出18.9%
-2.5%
两年增速更快
PCOR
近两年复合增速
1.3%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $359.3M | $311.4M |
| 净利润 | $-9.1M | $51.0M |
| 毛利率 | 80.1% | 66.9% |
| 营业利润率 | 15.5% | 24.2% |
| 净利率 | -2.5% | 16.4% |
| 营收同比 | 15.7% | -1.5% |
| 净利润同比 | 72.4% | 126.0% |
| 每股收益（稀释后） | $-0.06 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCORTECH
| Q1 26 | $359.3M | $311.4M | ||
| Q4 25 | $349.1M | $295.9M | ||
| Q3 25 | $338.9M | — | ||
| Q2 25 | $323.9M | $317.0M | ||
| Q1 25 | $310.6M | $316.2M | ||
| Q4 24 | $302.0M | $297.0M | ||
| Q3 24 | $295.9M | $289.5M | ||
| Q2 24 | $284.3M | $306.1M |
净利润PCORTECH
| Q1 26 | $-9.1M | $51.0M | ||
| Q4 25 | $-37.6M | $38.0M | ||
| Q3 25 | $-9.1M | — | ||
| Q2 25 | $-21.1M | $-17.7M | ||
| Q1 25 | $-33.0M | $22.6M | ||
| Q4 24 | $-62.3M | $34.9M | ||
| Q3 24 | $-26.4M | $33.6M | ||
| Q2 24 | $-6.3M | $40.6M |
毛利率PCORTECH
| Q1 26 | 80.1% | 66.9% | ||
| Q4 25 | 80.1% | 64.6% | ||
| Q3 25 | 79.7% | — | ||
| Q2 25 | 79.1% | 62.7% | ||
| Q1 25 | 79.1% | 67.9% | ||
| Q4 24 | 81.2% | 65.3% | ||
| Q3 24 | 81.4% | 63.2% | ||
| Q2 24 | 83.1% | 66.4% |
营业利润率PCORTECH
| Q1 26 | 15.5% | 24.2% | ||
| Q4 25 | -12.3% | 18.4% | ||
| Q3 25 | -4.4% | — | ||
| Q2 25 | -9.3% | -7.5% | ||
| Q1 25 | -11.7% | 12.2% | ||
| Q4 24 | -21.9% | 16.0% | ||
| Q3 24 | -12.3% | 13.8% | ||
| Q2 24 | -5.2% | 15.0% |
净利率PCORTECH
| Q1 26 | -2.5% | 16.4% | ||
| Q4 25 | -10.8% | 12.8% | ||
| Q3 25 | -2.7% | — | ||
| Q2 25 | -6.5% | -5.6% | ||
| Q1 25 | -10.6% | 7.1% | ||
| Q4 24 | -20.6% | 11.7% | ||
| Q3 24 | -8.9% | 11.6% | ||
| Q2 24 | -2.2% | 13.3% |
每股收益（稀释后）PCORTECH
| Q1 26 | $-0.06 | $0.32 | ||
| Q4 25 | $-0.25 | $0.24 | ||
| Q3 25 | $-0.06 | — | ||
| Q2 25 | $-0.14 | $-0.11 | ||
| Q1 25 | $-0.22 | $0.14 | ||
| Q4 24 | $-0.42 | $0.22 | ||
| Q3 24 | $-0.18 | $0.21 | ||
| Q2 24 | $-0.04 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $386.0M | $209.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $2.1B |
| 总资产 | $2.1B | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCORTECH
| Q1 26 | $386.0M | $209.8M | ||
| Q4 25 | $768.5M | $172.9M | ||
| Q3 25 | $684.0M | — | ||
| Q2 25 | $620.9M | $162.2M | ||
| Q1 25 | $566.7M | $140.7M | ||
| Q4 24 | $775.4M | $177.5M | ||
| Q3 24 | $756.9M | $187.5M | ||
| Q2 24 | $735.4M | $152.9M |
总债务PCORTECH
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
股东权益PCORTECH
| Q1 26 | $1.2B | $2.1B | ||
| Q4 25 | $1.3B | $2.0B | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | $1.9B | ||
| Q1 25 | $1.2B | $2.0B | ||
| Q4 24 | $1.3B | $2.1B | ||
| Q3 24 | $1.3B | $2.1B | ||
| Q2 24 | $1.3B | $2.1B |
总资产PCORTECH
| Q1 26 | $2.1B | $2.6B | ||
| Q4 25 | $2.2B | $2.5B | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.0B | $2.6B | ||
| Q1 25 | $1.9B | $2.6B | ||
| Q4 24 | $2.1B | $2.7B | ||
| Q3 24 | $2.0B | $2.7B | ||
| Q2 24 | $2.0B | $2.7B |
负债/权益比PCORTECH
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $76.8M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流PCORTECH
| Q1 26 | $76.8M | — | ||
| Q4 25 | $114.9M | — | ||
| Q3 25 | $88.5M | — | ||
| Q2 25 | $30.8M | $98.2M | ||
| Q1 25 | $66.0M | $41.1M | ||
| Q4 24 | $29.1M | $84.3M | ||
| Q3 24 | $39.3M | $63.9M | ||
| Q2 24 | $58.7M | $75.5M |
自由现金流PCORTECH
| Q1 26 | — | — | ||
| Q4 25 | $109.2M | — | ||
| Q3 25 | $83.1M | — | ||
| Q2 25 | $27.9M | $93.3M | ||
| Q1 25 | $62.0M | $31.0M | ||
| Q4 24 | $17.4M | $77.5M | ||
| Q3 24 | $35.7M | $54.7M | ||
| Q2 24 | $56.8M | $57.5M |
自由现金流率PCORTECH
| Q1 26 | — | — | ||
| Q4 25 | 31.3% | — | ||
| Q3 25 | 24.5% | — | ||
| Q2 25 | 8.6% | 29.4% | ||
| Q1 25 | 20.0% | 9.8% | ||
| Q4 24 | 5.8% | 26.1% | ||
| Q3 24 | 12.1% | 18.9% | ||
| Q2 24 | 20.0% | 18.8% |
资本支出强度PCORTECH
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 0.9% | 1.5% | ||
| Q1 25 | 1.3% | 3.2% | ||
| Q4 24 | 3.9% | 2.3% | ||
| Q3 24 | 1.2% | 3.2% | ||
| Q2 24 | 0.7% | 5.9% |
现金转化率PCORTECH
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCOR
暂无分部数据
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
